About Antiva Biosciences
Antiva Biosciences is a private company based in Redwood City, California. It has reported $96,794,613 raised in eight offerings on Form D since March 2013. Its chief executive is Kristine Ball.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 24, 2023 | May 5, 2023amended Oct 11, 2024 | $38,535,985of $52.9M target | 21 | $1.8M | Equity, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Oct 25, 2021 | Nov 3, 2021 | $15,639,364of $31.0M target | 20 | $781K | EquityRule 506(b) | Form D ↗ |
| Jul 6, 2018 | Jul 19, 2018 | $15,000,000fully sold | 8 | $1.8M | Equity, Securities on exerciseRule 506(b) | Form D ↗ |
| Feb 15, 2017 | Apr 5, 2017amended Aug 28, 2017 | $14,740,756of $25.9M target | 15 | $982K | Equity, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| May 27, 2015 | Jun 11, 2015 | $8,907,483of $15.9M target | 26 | $342K | EquityRule 506(b) | Form D ↗ |
| Dec 8, 2014 | Dec 23, 2014 | $1,745,019of $2.5M target | 19 | $91,843 | EquityRule 506(b) | Form D ↗ |
| Jun 24, 2014 | Jul 10, 2014 | $1,100,000of $1.3M target | 14 | $78,571 | DebtRule 506(b) | Form D ↗ |
| Feb 26, 2013 | Mar 6, 2013amended Sep 5, 2013 | $1,126,006fully sold | 18 | $62,556 | Equity06 | Form D/A ↗1 earlier filing |
| Total, eight offerings | $96,794,613 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Antiva Biosciences's Form D filed Oct 11, 2024.
Earlier filings also listed Vinzenz Ploerer (director, last listed Nov 2021), Steven James (director, last listed Nov 2021), Oranee Daniels (executive officer, last listed Nov 2021), Jenny Yip (director, last listed Nov 2021), David Kabakoff (director, last listed Nov 2021), Benjamin Rovinski (director, last listed Nov 2021), Ting Jia (director, last listed Jul 2018) and Raju Gadiraju, Ph.D. (executive officer, last listed Jul 2018).